Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2009

Greater occipital nerve stimulation via the Bion microstimulator:
Implantation technique and stimulation parameters clinical trial:
NCT00205894
Terrence L. Trentman
Mayo Clinic Arizona

David M. Rosenfeld
Mayo Clinic Arizona

Bert B. Vargas
Center for Neurosciences

Todd J. Schwedt
Washington University School of Medicine in St. Louis

Richard S. Zimmerman
Mayo Clinic Arizona

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Trentman, Terrence L.; Rosenfeld, David M.; Vargas, Bert B.; Schwedt, Todd J.; Zimmerman, Richard S.;
and Dodick, David W., ,"Greater occipital nerve stimulation via the Bion microstimulator: Implantation
technique and stimulation parameters clinical trial: NCT00205894." Pain Physician. 12,3. . (2009).
https://digitalcommons.wustl.edu/open_access_pubs/8168

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Authors
Terrence L. Trentman, David M. Rosenfeld, Bert B. Vargas, Todd J. Schwedt, Richard S. Zimmerman, and
David W. Dodick

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/
open_access_pubs/8168

Pain Physician 2009; 12:621-628 • ISSN 1533-3159

Clinical Report
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Background: Millions of patients suffer from medically refractory and disabling
primary headache disorders. This problem has led to a search for new and innovative
treatment modalities, including neuromodulation of the occipital nerves.
Objectives: The primary aim of this study is to describe an implantation technique
for the Bion® microstimulator and document stimulation parameters and stimulation
maps after Bion placement adjacent to the greater occipital nerve. The secondary aim
is to document outcome measures one year post-implant.
Design: Prospective, observational feasibility study.
Methods: Nine patients with medically refractory primary headache disorders
participated in this study. Approximately 6 months after Bion insertion, stimulation
parameters and maps were documented for all patients. At one year, outcome
measures were collected including the Migraine Disability Assessment Score.
Results: At 6 months, the mean perception threshold was 0.47 mA, while the
mean discomfort threshold was 6.8 mA (stimulation range 0.47 – 6.8 mA). The mean
paresthesia threshold was 1.64 mA and the mean usage range was 16.0. There were
no major complications reported such as device migration, infection, or erosion. One
patient stopped using her Bion before the 12-month follow-up visit. At one year, 7
of the 8 patients were judged as having obtained fair or better results in terms of
reduction of disability; 5 patients had greater than a 90% reduction in disability.
Limitations: Small, heterogeneous patient population without control group. Not
blinded or randomized.
Conclusion: The Bion can be successfully inserted adjacent to the greater occipital
nerve in an effort to treat refractory primary headache disorders. This microstimulator
may provide effective occipital stimulation and headache control while minimizing the
risks associated with percutaneous or paddle leads implanted subcutaneously in the
occipital region.
Key words: Chronic headache, migraine, cluster headache, peripheral nerve
stimulation
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igraine is the most common form of
disabling primary headache, affecting
12% of Caucasian populations (1). Cluster
headache and hemicrania continua, although much
less common, also have a significant negative impact
on quality of life (2,3). Subcutaneous occipital nerve
stimulation (ONS) has been reported to effectively
treat medically refractory primary headache disorders.
A number of recent studies have documented efficacy
outcomes and stimulation parameters associated with
ONS (4-10). These studies document off-label use of
spinal cord stimulation technology to stimulate the
distal branches of the C1-3 nerve roots. Prospective,
multicenter studies are underway to determine the
safety and efficacy of this modality (11).
The implantable Bion microstimulator was initially developed as a radiofrequency (RF) powered
functional electrical stimulator (12). However, the
Bion microstimulator (from Boston Scientific Neuromodulation Corporation, Valencia, CA) (Fig. 1) used in
this study is the only battery powered microstimulator
of its type and as such does not require an external
RF power source. It includes a single cathode on one
end and a single anode on the other. Currently an
investigational device, the Bion contains a programmable microchip, stimulating electrodes, telemetry
capability, and a transcutaneously rechargeable (3
milliamp hours) lithium ion battery (13). It is expected
that the battery will lose no more than 30% of its capacity after 500 cycles of full charge and discharge.

Fig. 1. The Bion microstimulator.
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The Bion microstimulator’s small size (27.5 mm x 3.2
mm) allows implantation adjacent to nerves via a less
invasive technique than utilizing spinal cord stimulation technology. Previous studies have evaluated Bion
implantation for pudendal nerve neuromodulation in
the setting of refractory detrusor overactivity incontinence (14,15). At our institution, we have implanted 9
Bion microstimulators adjacent to the greater occipital
nerve (GON) in an effort to treat refractory headache
disorders.
The primary aim of this feasibility study is to describe an implantation technique for the Bion microstimulator and document stimulation parameters and
stimulation maps after Bion placement adjacent to
the GON. The secondary aim is to document outcome
measures one year post-implant.

Methods
After the United States Food and Drug Administration (IDE G030225) and Institutional Review Board
approval of this feasibility study, 9 patients diagnosed
with chronic migraine or chronic cluster headache
presenting to our clinic were screened for inclusion
and exclusion. All 9 patients met the inclusion and exclusion criteria and all agreed to participate. Written
informed consent was obtained from each. Inclusion
criteria included 18 years of age or older, 12 or more
months of chronic migraine or chronic cluster headache, refractory to at least 4 preventative medications
used at adequate dosage for adequate duration of
time, willingness to maintain current pain medication regimen during the study, and willingness and
ability to maintain a headache diary for the duration
of the study. Exclusion criteria included pregnancy or
planned pregnancy, previous surgery in the occipital
region, and participation in a device or drug trial within the previous 30 days.
All patients underwent a detailed neurologic
exam and were assigned a diagnosis based on the International Classification of Headache Disorders – II
(16). Six patients had chronic cluster headache including one with migraines and one with hemicrainia continua, and 3 patients had chronic migraine only (Table
1). Each patient underwent a psychiatric evaluation
to determine their psychological stability to undergo
the procedure. The patients did not undergo a trial of
stimulation or occipital nerve block before implantation of the Bion.
For the purposes of this study, and consistent with
our previous study on occipital stimulation mapping
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Table 1. Patient demographics, 6-month Bion microstimulator usage and Migraine Disability Assessment Scores (MIDAS).
Diagnosis

Stimulator Usage

Pulse
Width
(us)

Rate (PPS)

Baseline
MIDAS**

1 – 72f†

Migraine

0.5-1.5 hrs/day

250

60

130-85-4

2 – 39f

Migraine

0.5 hrs,
2-3 days/wk

300

55

235-80-4

5-5-5

Excellent

3 – 44f

Cluster

0.5-0.75
hrs/2 wks

350

60

270-90-6

260-87-6

Poor

4 – 66f

Cluster

5-6 hrs/day

200

45

147-82-7

8-40-7

Excellent

5 – 46m

Cluster

22 hrs/day

250

55

225-90-7

130-80-5

Fair

6 – 44f

Cluster / hemicrania
continua

16 hrs/day

350

45

87-90-5

8-25-4

Excellent

7 – 60m

Migraine

18 hrs/day

250

45

108-90-6

6-90-4

Excellent

8 – 44m

Cluster

24 hrs/day

300

60

120-88-6

10-85-3

Excellent

9 – 35m

Cluster/Migraine

20 hrs/day

200

45

110-90-7

70-60-7

Fair

Patient

*Response key:				
> 90% reduction in disability = excellent		
70–90% reduction in disability = very good
50–69% reduction in disability = good
25–49% reduction in disability = fair
< 25% reduction in disability = poor

1 year
MIDAS**

Response*
Did not complete
study

PPS = pulse per second
†4 month visit

** The first number of each 3 digit series is the Migraine Disability Assessment Score, the second number is the number of headache days
over a 3-month period, and the third number is the average severity of each headache.

(9), the following definitions were used: perception
threshold is the lowest current amplitude that elicits
sensation. Perception threshold is assumed to represent local tissue stimulation, while the upper end of
the stimulation range (discomfort threshold) is defined as the current amplitude where patients feel
stimulation strongly and do not wish the stimulation
to be increased any further. The stimulation range
(perception through discomfort threshold) represents
the useful amplitudes for any given electrode combination while the usage range (discomfort threshold
divided by perception threshold) “represents the relative size of the therapeutic stimulating window” (17).
Paresthesia threshold is the current amplitude where
the patient first noted stimulation traveling toward
the vertex of his head, suggesting direct GON stimulation. The maximum stimulation tested during the
study was 10 milliamps (mA).
The Bion implantation procedure was carried out
under monitored anesthesia care in the prone position.
Antibiotic prophylaxis was given to each patient before
incision. The goal of each implant was to position the
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Bion microstimulator subcutaneously in the occipital
region at a right angle to the GON, with the cathode
immediately adjacent to the nerve. The anatomy of this
region has recently been reviewed (8,18), and a cadaver
study noted that in 10 specimens (20 nerves), the GON
ascended between 5 and 28 mm from the midline at
the level of the intermastoid line (19).
First, using fluoroscopic guidance, a line was
drawn between the tips of the mastoid processes (intermastoid line) and in the midline. After sterile prep
and injection of local anesthetic for skin wheal, a small
(< 1 cm) incision was made 3 cm contralateral to the
side of intended GON stimulation. Next, a 20-gauge, 15
cm insulated stimulating needle was inserted through
the incision and across the midline toward the side to
be stimulated. The ideal depth was estimated to be
below the dermis but superficial to the fascia, in the
subcutaneous fat layer. The location of the GON was
marked as the point where the patient experienced
maximal stimulation induced paresthesia towards the
vertex of their head, at least to the level of the top of
the ear.
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Next, the stimulating needle was removed and
the Bion introducer with the dissector/stimulator was
inserted through the incision. The Bion dissector/stimulator was used to confirm the location of the GON,
after which the Bion was deployed adjacent to the
GON using the Bion placement tool and holder (Figs.
2,3).
Post implantation management included device
activation 7–10 days postoperatively in 7 of the patients and activation on the day of implant in 2 patients. The timing of device activation was based on
patient preference and travel considerations. The patients were initially given a radiofrequency “pillow”
charger; a smaller “butterfly” charger subsequently
became available that could be attached to a hat,
allowing the patient to recharge while upright. The
patients were instructed to initially use the Bion constantly at low amperage and then to increase the amperage as needed to treat intermittent headache exacerbations. However, they were given the prerogative
to adjust use to comfort and effect. Patients turned
stimulation on or off, and adjusted the amplitude of
stimulation, via a wireless remote control.
Approximately 6 months after implantation, the
following data were gathered in addition to the data

Fig. 2. The Bion placement tools and holder.
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collected as part of the sponsored study: headache location, average number of hours of Bion use per day,
frequency of recharging, pulse width and rate, perception threshold with associated paresthesia map,
discomfort threshold with associated paresthesia map,
and paresthesia threshold. The patients were given a
map of the head (Fig. 4) to allow them to identify the
location of their baseline headaches and areas where
they perceived stimulation. Mean values with standard
deviation (SD) were used to summarize the data.
Migraine Disability Assessment Scores (MIDAS)
were obtained prior to and at 12 months after implantation of the stimulator. The MIDAS questionnaire is a
validated headache-related disability instrument that
is increasingly used as a surrogate measure of outcome
in episodic and chronic migraine trials (20). The 5-question instrument quantifies time lost due to headache
from work, school, household work, and social/family
or leisure activities over the preceding 3 months. The
score is typically reported in a 3-digit format (e.g. 10675-7): The first number is the MIDAS (greater than 20
is considered severe), the second number is the number of days in the past 3 months that the patient had a
headache (max 90), and the third number is the average severity of each headache (0–10 scale).

Fig. 3. AP skull film showing Bion after insertion. The
device is subcutaneous in the occipital region.
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Fig. 4. Head maps used to identify areas of baseline headache, perception threshold, and discomfort threshold. Used with permission. Trentman et al (9) and the International Neuromodulation Society.

Results
All 9 patients invited to participate signed informed consent. One patient completed the headache maps approximately 4 months after implant. She
subsequently did not appear for her 6-month followup and stopped using the Bion before study completion at 12 months. She stated the battery recharging
schedule was too demanding, specifically that she was
spending 1.5 hours recharging her Bion for every 1.5
hours of use. Patient demographics, baseline usage
data, and MIDAS are summarized in Table 1. The mean
decrease in number of days with headache for the 8
patients who completed the study was 28.5 (SD 29.6),
while the average headache severity score decreased
by 0.88 (SD 1.36). More detailed outcome data continues to be analyzed and will be presented separately.
Self-reported stimulator usage ranged from 30
minutes every 2 weeks to 24 hours/day (mean 12.2
hours/day, median 16 hours/day), and recharging frequency ranged from 35 minutes per week to 4 hours
per day (mean 1.67 hours/day, median 1.5 hours/day).
Distribution of baseline headache and stimulation
thresholds (perception and discomfort) are shown in
Table 2 (see Fig. 4 for maps). The zones of stimulation as noted in Table 2 are not meant to imply that
the patients felt paresthesia throughout the entire
zone; rather, they recorded stimulation in some part
of each area noted. Table 3 summarizes stimulation
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parameters, including a mean perception threshold of
0.47 mA and a mean discomfort threshold of 6.8 mA
(stimulation range 0.47 – 6.8 mA). The mean paresthesia threshold was 1.64 mA, and the mean usage
range was 16.0. The average tissue impedance was
1.34 kilo-ohms.
No patients reported major device-related complications during the 12-month duration of the study
Table 2. Headache and Stimulation Distribution (See Fig. 4).
This data was obtained at the 6-month follow-up visit (except
where noted) in addition to the data collected as part of the
sponsored study.
Patient

Location
of Baseline
Headache

Location of
Perception
Threshold

Location of
Discomfort
Threshold

1†

1,2,10,11

7,9,18

7

2

5 – 7,9

9

5,7,9

3

10 – 12,14 – 16

16,18

16,18

4

2 – 7, 9,18

7,9

5 – 7,9

5

10,16

16

14 – 16

6

10 – 12,14,16

16

7,14,16

7

10,12,15

18

14,16,18

8

10 – 12

18

7,9,16 – 18

9

1,5,6

1,5 – 7, 9

1,5 – 7,9

†Four month visit.
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Table 3. Bion Tested Stimulation Parameters. This data was obtained at the 6-month follow-up visit (except where noted) in addition to the data collected as part of the sponsored study.
Patient

Perception Threshold
(mA)

Discomfort Threshold
(mA)

Paresthesia Threshold
(mA)

Usage Range*

1†

0.6

10.0

1.8

16.67

2

0.2

5.4

1.6

27.0

3

0.4

1.6

1.2

4.0

4

0.2

2.2

0.6

11.0

5

0.8

10.0

1.6

12.5

6

0.4

10.0

4.0

25.0

7

0.4

6.2

1.6

15.5

8

0.8

5.8

1.6

7.25

9

0.4

10.0

0.8

25.0

Mean (SD)

0.47 (0.22)

6.8 (3.4)

1.64 (0.97)

16.0(8.2)

Median

0.4

6.2

1.6

15.5

*Usage range = discomfort threshold divided by perception threshold. †Four month visit.

such as infection, migration, or erosion. Adverse events
reported after the study was complete at 12 months
included loss of stimulation (N = 1). The patient’s Bion
had malfunctioned and was unrechargeable, requiring
replacement. This patient subsequently experienced
an infection necessitating explant and reimplant of a
third Bion. Minor adverse events included 2 patients
who complained of muscle stimulation at high amplitudes, and one patient who complained of pain near
the implant site.

Discusson
Millions of patients suffer from primary headache
disorders; a portion of them, like the patients in this
study, endure severe, medically refractory pain. This
problem has led to a search for new and innovative
treatment modalities, including neuromodulation of
the occipital nerves.
A number of recent studies have suggested that
stimulation of the distal branches of the C1-2-3 nerve
roots can produce pain relief in patients with otherwise
refractory headache disorders (21-24). The mechanism
of analgesia may be due to inhibition of nociceptive
specific neurons in the trigeminal-cervical complex.
Electrical stimulation of the GON may also result in mobilization of central pain modulatory centers (25,26).
Of note, we previously reported pain relief despite
persistent cranial autonomic activity (lacrimation, rhinorrhoea, conjunctival injection) in 2 of these patients
implanted with Bions (27). One patient was diagnosed
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with cluster headache, while the other was diagnosed
with hemicrania continua. This separation of autonomic
signs from analgesia suggests that the autonomic features and first division pain are dissociated and separately controlled from a supranuclear generator.
While previous occipital stimulation techniques
have resulted in diffuse distal C1-2-3 stimulation via
cylindrical (percutaneous) or paddle (surgical) spinal
cord stimulator (SCS) leads (4-7), the Bion was used
here to stimulate a limited area and a specific nerve
(GON). Our approach assumed that GON stimulation
will have the same central analgesic affect as more
diffuse C1-2-3 stimulation via percutaneous stimulator
leads. If this assumption is correct, clinicians may be
able to achieve the benefits of occipital stimulation
via a microstimulator while circumventing the technical problems associated with occipital percutaneous
leads and remote power sources.
In terms of stimulation parameters and the Bion,
all of the patients had a sensory threshold of less than
one milliamp, suggesting local tissue stimulation,
while several patients had discomfort thresholds at
the maximum tested amplitude of 10 mA. The mean
paresthesia threshold of 1.64 mA suggests that at this
amperage the GON was being stimulated directly. The
large usage range (16.0, SD 8.2) indicates wide variation between these patients in terms of the size of
their therapeutic stimulating windows. Lengthy daily
usage time and high rates of stimulation (pulses per
second) will increase recharging frequency.

www.painphysicianjournal.com
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Our previous study on occipital paresthesia mapping in patients with subcutaneously implanted SCS
leads provides several points for comparison (9). In that
study, the mean perception threshold was higher (1.07
V), while the discomfort threshold (3.63 V) was lower
than the Bion (Table 3). The average tissue impedance
in this study (1.34 kilo-ohms) is close to 1.0 kilo-ohms,
allowing us to assume that the mA recorded for the
Bion are roughly equivalent to the volts recorded in
our previous study of SCS leads. The Bion’s proximity to
the GON may explain its lower perception threshold,
while the reason for the higher discomfort threshold
for the Bion is more obscure. Diffuse tissue stimulation
produced by SCS leads may increase the likelihood of
patient discomfort.
In terms of paresthesia mapping, it is difficult to
determine if a correlation exists between distribution
of paresthesia (Table 2 and Fig. 4) and outcome, but
a pattern did not appear to emerge. Despite the Bion’s small size, we were able to produce paresthesia
in remote areas of the head, including at least one
patient who noted trigeminal distribution paresthesia. It is unknown if outcome is improved by covering
patient’s baseline headache regions with paresthesia,
analogous to spinal cord stimulation.
The MIDAS was used as a measure of outcome in
this study. At one year, 7 of the 8 patients were judged
as having obtained fair or better results in terms of
reduction of disability; 5 patients had greater than
90% reduction in disability. All patients with excellent
outcomes experienced a > 50% reduction in headache
days and/or 30–50% reduction in average headache severity, while patients with a fair response experienced
a reduction in headache days or severity of 25–50%.
The Bion’s small size and low profile may help
minimize or eliminate device displacement and lead
breakage problems associated with SCS equipment
implanted subcutaneously in the occipital region. As
recently reviewed (10), complications of SCS systems
implanted in the occipital region can occur frequently
with lead migration rates as high as 100%. Other reported complications include lead fracture or disconnection, infection, erosion, and allergic reaction.
The Bion microstimulator requires no anchoring
or tunneling of extensions to remote power sources;
as such, much of the mechanical stress on the occipital stimulator system is eliminated. However, it is possible that a foreign body such as the Bion can move
within tissue planes or become encapsulated, hence
increasing the energy required to stimulate the oc-
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cipital nerve. As a current controlled device, the Bion
has the (limited) ability to automatically adjust the
voltage to maintain the current amplitude despite
encapsulation.
Disadvantages of a microstimulator system include
the need for frequent recharging and limited choices
in terms of electrode combinations. Future versions of
this device may include a larger battery and multiple
electrodes.
Limitations of this feasibility study include its small
and heterogeneous patient population without a control group. It was neither randomized nor blinded. This
however was a pilot study to ascertain the feasibility
of the technique and potential for this modality in the
treatment of refractory primary headache disorders.
Thus far, there are no randomized controlled studies
published on the safety or efficacy of any occipital
nerve stimulation device for the treatment of primary
headache disorders. The results of this feasibility study
would support randomized controlled trials with the
Bion microstimulator in this patient population. Potentially, a blinded study could be carried out wherein
Bion microstimulators would be inserted in both a
treatment and a placebo group. The treatment group
would receive stimulation immediately after implant,
while the placebo group would not have their Bion
microstimulators activated for several months. A
blinded, head to head comparison of the Bion microstimulator to other ONS systems that use spinal cord
stimulation equipment could be more difficult to carry
out, as the spinal cord stimulators systems require a
remote battery implant. In this scenario, it would not
be possible to “blind” the patient as to which system
was implanted.

Conclusion
In conclusion, we have documented paresthesia
maps and stimulation parameters for 9 patients after
permanent implantation of a Bion microstimulator,
with one year outcome data. There were no major adverse events during the study period, including device
migration or infection. One patient did not complete
the study. Further studies are needed to evaluate the
safety and efficacy of subcutaneous C1-2-3 stimulation for headache disorders, including the use of microstimulators to stimulate specific nerves. If this novel
microstimulator is shown to be effective in randomized trials, it may be possible to achieve headache
control via neurostimulation with a low incidence of
long-term complications.
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